SHELTON, Connecticut, United States, April 7, 2026
NanoViricides, Inc., a clinical-stage biopharmaceutical company, announced that it has filed an application with the U.S. FDA Office of Orphan Products Development for Rare Pediatric Disease Drug (RPDD) designation for its lead antiviral candidate NV-387, targeting the treatment of measles, a highly contagious viral disease with no approved therapeutic options. The filing represents a significant step in advancing broad-spectrum antiviral drug development and regulatory strategy.
Regulatory Incentives Strengthen Development Strategy
The RPDD designation, if granted, would make NanoViricides eligible for a Priority Review Voucher (PRV) upon approval of NV-387, a valuable regulatory incentive that can be sold or used to accelerate FDA review timelines, with recent vouchers valued at approximately $150–160 million.
This incentive significantly enhances the commercial and strategic viability of NV-387, providing both financial upside and accelerated regulatory pathways. The program was recently reinstated under the Consolidated Appropriations Act of 2026, reinforcing the importance of rare pediatric disease drug development in the United States.
The RPDD application is expected to complement the company’s earlier Orphan Drug Designation filing, further strengthening the regulatory framework supporting NV-387’s development and positioning it for expedited clinical and commercial advancement.
Advertisement
Rising Measles Cases Highlight Urgent Medical Need
The filing comes amid a resurgence of measles cases globally and in the United States, with 1,661 confirmed cases reported across 33 states in 2026, alongside multiple outbreaks and increasing international spread.
Despite the availability of vaccines, declining vaccination rates and vaccine hesitancy have contributed to rising infection rates, while infants under nine months remain ineligible for routine vaccination, creating a vulnerable population with limited protection.
NanoViricides highlighted that NV-387 has demonstrated strong antiviral activity in preclinical studies, including protection against lethal measles infection in animal models, suggesting its potential as a first-in-class therapeutic option for this disease.
Broad-Spectrum Antiviral Platform Expands Clinical Potential
NV-387 is part of NanoViricides’ proprietary nanomedicine platform, designed to mimic host cell structures and neutralize viruses by binding and disabling them, making it difficult for viruses to develop resistance. The drug has shown activity against a wide range of pathogens, including influenza, RSV, COVID-19, mpox, and smallpox, positioning it as a versatile antiviral candidate.
The company is advancing NV-387 toward Phase II clinical trials, with the goal of addressing multiple viral infections using a single broad-spectrum therapeutic approach, which could significantly enhance pandemic preparedness and global health response capabilities.
Furthermore, the potential use of NV-387 for preventive treatment of exposed individuals could reduce the need for quarantine measures, providing both clinical and economic benefits while improving patient outcomes.
NanoViricides’ RPDD application for NV-387 underscores the growing importance of innovative antiviral therapies and regulatory incentives in addressing emerging infectious diseases. With no approved treatment currently available for measles and rising global case numbers, the development of effective, broad-spectrum antiviral solutions is critical.
By leveraging advanced nanomedicine technology, strong preclinical data, and strategic regulatory pathways, NanoViricides is positioning NV-387 as a potential breakthrough therapy in infectious disease management, highlighting the role of biopharmaceutical innovation in improving global health outcomes.
Source: NanoViricides press release
